T1	Participants 194 265	patients with unresectable stage IIIA and B non-small-cell lung cancer.
T2	Participants 447 637	Eligible patients were treatment naive, and had stage IIIA and B unresectable non-small-cell lung cancer, Eastern Cooperative Oncology Group performance status 0/1, and normal organ function
T3	Participants 1085 1106	141 patients enrolled
